Tumor Differentiation
Tumor Differentiation - Related Videos
08:42
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
0 Views •
Cited by 4 •
2025
The protocol describes a method for creating a patient-derived colorectal cancer (CRC) organoid model co-cultured with tumor-infiltrating lymphocytes (TILs) to study their interactions and therapeutic potential. This model provides a preclinical platform to explore immune responses in the tumor microenvironment and to predict the efficacy of TIL-based therapy for personalized CRC treatment.
10:04
Enhancing Tumor Content through Tumor Macrodissection
0 Views •
Cited by 5 •
2022
This protocol presents a method to increase the percent tumor content of formalin-fixed paraffin-embedded tissue samples.
02:31
FFPE Tumor Tissue Macrodissection: A Technique to Obtain Specific Tumorous Tissue from Unstained Specimens
0 Views •
2023
This video describes a method for the manual macrodissection of cancer tissue from unstained tissue specimens to obtain a specific cancer tissue. The tissue section can be processed further to obtain DNA for genome-wide studies on gastrointestinal cancers.
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
0 Views •
Cited by 9 •
2017
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
FAQs
Genetic and epigenetic changes can disrupt the normal maturation programs that maintain specialized cell structure and function. As these regulatory changes accumulate, malignant cells may lose features associated with their tissue of origin, producing a spectrum from retained specialization to markedly abnormal maturation. This biological shift helps explain why differentiation can reflect aspects of tumor progression and behavior.
Pathologists examine tissue architecture, cellular appearance, and lineage-associated markers to evaluate differentiation. Histology reveals how cells and tissue structures are organized, while immunohistochemistry identifies markers that support a particular cellular origin or phenotype. Considering these findings together can strengthen tumor classification, especially when morphology alone does not clearly establish the tumor type.
Differentiation and grade provide related but distinct information in cancer assessment. Differentiation focuses on how closely malignant cells retain characteristics of their originating tissue, whereas grade is considered alongside that finding to help characterize biological behavior. Using both assessments gives clinicians and pathologists a broader basis for estimating prognosis and supporting treatment decisions.
Assessment begins with examination of tumor tissue using histology, which permits evaluation of architecture and cellular morphology. When additional clarification is needed, immunohistochemistry can identify relevant markers and help support classification. The resulting differentiation findings are interpreted with other pathological information, including tumor grade, to produce a more informative diagnostic and prognostic assessment.
Tumor differentiation can help distinguish among tumor types by showing whether malignant cells retain recognizable structural or functional features of a particular tissue. Histological patterns and immunohistochemical markers provide complementary evidence for this interpretation. Accurate classification is clinically important because it contributes to estimates of biological behavior and informs decisions about how the cancer should be managed.
Differentiation findings contribute to treatment planning by helping clinicians interpret tumor identity, expected biological behavior, and prognosis. In research, the loss or retention of specialized characteristics provides a framework for studying tumor progression. It also supports investigation of differentiation-based therapies, which seek to use cellular maturation states as a relevant basis for therapeutic development.